BioCentury | Oct 6, 2017
Company News

NIAID exercises option to develop MGD014 from MacroGenics

...September 2015 deal and will provide up to $10.8 million in development funding to advance MGD014...
...MGD014, a bispecific antibody targeting CD3 and HIV-infected cells developed using DART technology. MacroGenics believes MGD014...
...products. MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. National Institutes of Health , Bethesda, Md. Business: Infectious Shannon Lehnbeuter CD3 x HIV DART molecule MGD013 MGD014 MacroGenics...
BioCentury | Oct 22, 2015
Distillery Therapeutics

Therapeutics: CD3; HIV env

...the anti-CD3/HIV env DART in animal models of HIV infection. MacroGenics Inc. has MGD014 ( CD3 x HIV DART molecule...
Items per page:
1 - 2 of 2